163 related articles for article (PubMed ID: 32203949)
1. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
Hu Z; Zheng B; Xu J; Gao S; Lu W
Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
4. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
6. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
7. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy.
Hu Y; Chen X; Xu Y; Han X; Wang M; Gong T; Zhang ZR; John Kao W; Fu Y
Nanoscale; 2019 Sep; 11(35):16476-16487. PubMed ID: 31453622
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.
Qian F; Villella J; Wallace PK; Mhawech-Fauceglia P; Tario JD; Andrews C; Matsuzaki J; Valmori D; Ayyoub M; Frederick PJ; Beck A; Liao J; Cheney R; Moysich K; Lele S; Shrikant P; Old LJ; Odunsi K
Cancer Res; 2009 Jul; 69(13):5498-504. PubMed ID: 19491279
[TBL] [Abstract][Full Text] [Related]
12. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
13. An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy.
Zhao Y; Cai C; Liu M; Zhao Y; Pei W; Chu X; Zhang H; Wang Z; Han J
Colloids Surf B Biointerfaces; 2019 Nov; 183():110394. PubMed ID: 31398618
[TBL] [Abstract][Full Text] [Related]
14. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles.
Calleja P; Irache JM; Zandueta C; Martínez-Oharriz C; Espuelas S
Pharmacol Res; 2017 Dec; 126():77-83. PubMed ID: 28893628
[TBL] [Abstract][Full Text] [Related]
15. Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: In vitro/in vivo evaluation and binding properties investigation.
Zhao Y; Cai C; Liu M; Zhao Y; Wu Y; Fan Z; Ding Z; Zhang H; Wang Z; Han J
Int J Biol Macromol; 2020 Jun; 153():873-882. PubMed ID: 32169451
[TBL] [Abstract][Full Text] [Related]
16. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
17. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
[TBL] [Abstract][Full Text] [Related]
18. Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.
Salvadori ML; da Cunha Bianchi PK; Gebrim LH; Silva RS; Kfoury JR
Med Oncol; 2015 Nov; 32(11):248. PubMed ID: 26442514
[TBL] [Abstract][Full Text] [Related]
19. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.
Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J
J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005
[TBL] [Abstract][Full Text] [Related]
20. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]